Shifting the treatment
paradigm for autoimmune
disease toward Navacim™-directed
Parvus is pioneering a novel class of disease-modifying therapeutics – Navacims™ – that are designed to reverse autoimmune disease by selectively blunting the action of autoimmunity without impairing normal immunity.
Parvus’ therapeutic platform is based on the discoveries of Pere Santamaria, M.D., Ph.D., Professor in the Department of Microbiology & Infectious Diseases and Julia McFarlane Chair in Diabetes Research at the Cumming School of Medicine at the University of Calgary. Dr. Santamaria has published extensively in peer-reviewed journals, demonstrating that Navacims can induce disease- specific regulatory T lymphocytes (Tregs) to re-establish the regulatory function of the immune system in preclinical models of a variety of autoimmune diseases.
Shifting the Treatment Paradigm in Autoimmune Disease
Parvus’ mission is to shift the treatment paradigm toward Navacim-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from many different autoimmune diseases as well as other chronic inflammatory conditions.
Parvus is advancing a robust R&D pipeline of proprietary drug candidates towards clinical testing, including those R&D programs partnered with Genentech and Novartis. Parvus’ leadership team possesses deep experience in drug discovery, development, and commercialization in diverse disease areas, including in immunology and autoimmune disease.